论文部分内容阅读
目的探讨小细胞肺癌的治疗模式。方法 2008年以来收治的小细胞肺癌患者154例,对其临床特点和治疗情况进行分析,疗效评价依据实体瘤疗效反应评价标准。结果 68例广泛期患者1、2年生存率为57%和24%,中位生存期为14.4个月。86例局限期患者,1、2、5年生存率分别为81%、57%和19%;其中根治术后化疗8例,均存活,中位生存期41.7个月;根治术后化疗联合放疗,中位生存期为50.8个月;未手术患者化疗、未手术患者化疗联合放疗中位生存期为12.1个和27.6个月。结论多线治疗方案对于广泛期患者,可改善生存;放化疗联合治疗为局限期患者的首选治疗方案。
Objective To investigate the treatment of small cell lung cancer. Methods A total of 154 patients with small cell lung cancer who were admitted to our hospital since 2008 were analyzed for their clinical characteristics and treatment. The efficacy evaluation was based on the evaluation criteria of response to solid tumor. Results The overall 1-year and 2-year survival rates of 68 patients with extensive stage were 57% and 24%, respectively. The median survival time was 14.4 months. Eighty-six patients with limited duration had a 1, 2, 5 year survival rate of 81%, 57%, and 19% respectively. Among them, 8 patients underwent radical operation with a median survival time of 41.7 months. Radiotherapy combined with radiotherapy , And the median survival time was 50.8 months. The median survival time of non-operative chemotherapy and radiotherapy was 12.1 months and 27.6 months in patients without chemotherapy. Conclusions Multi-line therapy can improve survival in patients with extensive stage. Combination chemotherapy and radiotherapy is the preferred treatment for patients with limited stage.